Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 53: 1183-1185, 2007; 10.1373/clinchem.2007.087049
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parekh, F. K.
Right arrow Articles by Richie, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parekh, F. K.
Right arrow Articles by Richie, T. L.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:1183-1185.)
© 2007 American Association for Clinical Chemistry, Inc.


Editorials

Characterization of Immune Reactivity Profiles Using Microarray Technology May Expedite Identification of Candidate Antigens for Next Generation Malaria Vaccines

Falgunee K. Parekh and Thomas L. Richiea

Naval Medical Research Center, Silver Spring, MD

aAddress correspondence to this author at: Naval Medical Research Center, 503 Robert Grant Ave., Silver Spring, MD 20910.

The first 300 words of the full text of this article appear below.

Vaccines have proven to be one of the most successful and efficient means of controlling infectious diseases of public health importance, including smallpox, polio, pertussis, and measles (1). The annual global burden of 300–500 million new malaria cases and 1–3 million malaria-related deaths demonstrates the potential public health and socioeconomic benefit that would accrue with the deployment of a highly effective malaria vaccine, particularly for the most affected and impoverished populations (2). However, despite several decades of research and substantial evidence for its feasibility, such a vaccine remains elusive (3).

Among the many challenges facing vaccine developers is how to mine the human immune response to natural infection to identify protective antigens and associated host responses. While there is no evidence that sterile immunity is ever naturally induced by the parasite, both symptoms and parasite density gradually decline with repeated exposure, resulting in a state of clinical and partial parasitological immunity (4). Thus young children living in endemic areas are at the greatest risk for high-density infections and for clinical disease, including severe complications, whereas older children and adults are rarely symptomatic, although they may harbor and transmit the parasite. A variety of data implicate antibody responses to multiple blood stage antigens as the primary effector mechanism underlying naturally acquired immunity; the antigenic targets, however, have not been clearly identified. Our limited understanding of the array of protective (and nonprotective) immune responses is reflected by the small number of antigens under development as candidate vaccines or shown to be protective in experimental challenge models (5)(6). Indeed, current generation subunit vaccines are based on a few "traditional" antigens (7) despite evidence that antimalarial immunity is likely multifactorial, targeting many antigens and involving antibody responses, T cell responses, . . . [Full Text of this Article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.